Cnossen 2011.

Methods	Study design: open, parallel RCT Study duration: not reported Follow‐up period: 3 months
Participants	Country: Germany, Netherlands Setting: multicentre (2) PrevaIent adult patients on CAPD Number: treatment group (12); control group (11) Mean age ± SD (years): treatment group (70.0 ± 13.1); control group (55.3 ± 15.6) Sex (M/F): treatment group (9/3); control group (10/1) Exclusion criteria: intercurrent infection; use of 1.1% amino acids (Nutrineal, Baxter Healthcare); treatment with APD
Interventions	Treatment group Neutral pH, low GDP solution (Physioneal; Baxter Healthcare) Control group Standard PD fluid (Dianeal, Baxter Healthcare)
Outcomes	Advanced glycation end product concentrations RRF
Notes	Significant disparity in baseline age between the two groups noted. Author contacted, awaiting response
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Low drop‐out rate (3/26 (11.5%))
Selective reporting (reporting bias)	High risk	Limited reporting of clinical outcomes
Other bias	High risk	A large difference in baseline age between the treatment and control groups raise concern for inadequate randomisation